This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Kevin Douglas Stewart - Innovator in Antibody Formulations
Introduction: Kevin Douglas Stewart is an accomplished inventor based in Gaithersburg, MD (US). He currently works at AstraZeneca AB, where he focuses on developing innovative solutions in the field of biotechnology. Although he has not yet been granted any patents, his contributions to the field are noteworthy.
Latest Patent Applications: Kevin's latest patent applications include "Stable, Aqueous Formulations of Antibodies that Bind IL5 Receptor." This invention relates to stable, aqueous antibody formulations. In some embodiments, the stable, aqueous formulations comprise about 2 mg/mL to about 100 mg/mL of an anti-IL5R antibody, and about 0.002% to about 0.01% polysorbate-20. Additionally, the application provides methods of making and using such antibody formulations.
Conclusion: Kevin Douglas Stewart is a dedicated inventor whose work at AstraZeneca AB focuses on advancing antibody formulations. His innovative approaches have the potential to significantly impact the biotechnology industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile